Business
Jazz Pharmaceuticals Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023
Seven abstracts emphasize Jazz's commitment to advancing the care and understanding of debilitating sleep disorders such as narcolepsy and idiopathic
About this update from Jazz Pharmaceuticals Plc
[{"type":"text","content":"Seven abstracts emphasize Jazz's commitment to advancing the care and understanding of debilitating sleep disorders such as narcolepsy and idiopathic hypersomnia\nDUBLIN, May 31, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that seven abstracts featuring new data from across its sleep medicine portfolio will be presented at SLEEP 2023, the 37th annual meeting of the Associated Professional Sleep Societies (APSS) being held June 3-7, 2023. Presentations include four posters featuring real-world data on Xywav® (calcium, magnesium, potassium, and sodium oxybates), the first and only low-sodium oxybate, for the treatment of narcolepsy patients with cataplexy and/or excessive daytime sleepiness (EDS) and adult patients with idiopathic hypersomnia.\n\"For almost two decades, we have strived to develop innovative therapies and provide meaningful support for people living with challenging neurological conditions. This is exemplified through our development of low-sodium Xywav,\" said Kelvin Tan, MBBCh, MRCPCH, senior vice president and chief medical officer of Jazz Pharmaceuticals. \"As people living with narcolepsy or idiopathic hypersomnia have two-to-three times higher prevalence of cardiovascular comorbidities such as stroke and heart failure, and sodium is a modifiable risk factor for these cardiovascular conditions, having a low-sodium option is an important consideration for long-term health. Our data at SLEEP 2023 reaffirm our longstanding commitment to patient care and the sleep community. We look forward to sharing our research at the meeting and advancing the understanding of these multi-symptom and often underrecognized sleep disorders.\"\nHighlights at SLEEP 2023 include:\nIn idiopathic hypersomnia:A real-world claims analysis of the clinical burden of patients diagnosed with idiopathic hypersomnia, which found they experienced significantly higher prevalence of comorbidities, such as cardiovascular conditions and mood disorders, than those not diagnosed with the sleep disorder. These results are consistent with previous studies in other sleep disorders, including narcolepsy, and confirm the need for holistic treatment strategies that consider patients' overall clinical profile.In narcolepsy:Two posters on results of the real-world TENOR study of adults with narcolepsy transitioning from Xyre...